Acloproxalap is under clinical development by Aldeyra Therapeutics and currently in Phase II for Sicca Syndrome (Sjogren). According to GlobalData, Phase II drugs for Sicca Syndrome (Sjogren) does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Acloproxalap LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Acloproxalap (ADX-629) is under development for the treatment of plaque psoriasis, atopic (allergic) asthma, acute alcoholic hepatitis, cytokine storm, ethanol toxicity, chronic cough, minimal change disease, nephrotic syndrome, atopic dermatitis and Sjogren-Larsson syndrome and COVID-19. The drug candidate is RASP (Reactive Aldehydes Species-Pro-inflammatory) inhibitor, administered through oral route. It is an analog of reproxalap. It acts by targeting aldehyde load.
It was under development for non-alcoholic steatohepatitis (NASH) and inflammatory bowel disease (IBD).
Aldeyra Therapeutics overview
Aldeyra Therapeutics, is a biotechnology company. It offers treatment of immune-mediated diseases. The company offers product pipeline includes Reproxalap, ADX-2191, RASP-Inhibitor Discovery Platform, ADX-629, ADX-246 and ADX-248. Reproxalap is used to treat dry eye disease, allergic conjunctivitis and proliferative vitreoretinopathy. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment primary vitreoretinal lymphoma cancer, proliferative vitreoretinopathy, and retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss. It develops ADX-246 in systemic immune-mediated disease; and ADX-248 in geographic atrophy. Aldeyra Therapeutics is headquartered in Lexington, Massachusetts, the US.
For a complete picture of Acloproxalap’s drug-specific PTSR and LoA scores, buy the report here.